Insider · CIK 0002019645

Bruno Julianne

Reports to the SEC for 2 companies · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0002019645

Forms 4 and 5

Insider transactions

22 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-23	DMRADamora Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+37.3K sh	—	—	37,313
2026-02-09	DMRADamora Therapeutics, Inc. · Series C Preferred StockM Exercise/Conversion	Director	MExercise/Conversion	−129 sh	—	—	0
2026-02-09	DMRADamora Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+129K sh	—	—	137,032
2025-03-21	CRSPCRISPR Therapeutics AGS Sale	Chief Operating Officer	SSale	−1,714 sh	$41.23	−$70.7K	10,544
2025-03-20	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+3,750 sh	—	—	12,258
2025-03-20	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−3,750 sh	—	—	11,250
2025-03-14	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Chief Operating Officer	AAward	+36.7K sh	—	—	36,666
2025-03-14	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	Chief Operating Officer	AAward	+27.5K sh	—	—	27,500
2025-03-12	CRSPCRISPR Therapeutics AGS Sale	Chief Operating Officer	SSale	−190 sh	$43.32	−$8,230.8	8,508
2025-03-11	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−435 sh	—	—	0
2025-03-11	CRSPCRISPR Therapeutics AGS Sale	Chief Operating Officer	SSale	−1,198 sh	$42.42	−$50.8K	8,263
2025-03-11	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+435 sh	—	—	8,698
2025-03-10	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−2,399 sh	—	—	4,796
2025-03-10	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+2,399 sh	—	—	9,461
2025-02-19	CRSPCRISPR Therapeutics AGS Sale	Chief Operating Officer	SSale	−333 sh	$52.80	−$17.6K	7,062
2025-02-18	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−650 sh	—	—	650
2025-02-18	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+650 sh	—	—	7,395
2024-10-16	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	Chief Operating Officer	AAward	+18.3K sh	—	—	18,333
2024-06-21	CRSPCRISPR Therapeutics AGS Sale	Chief Operating Officer	SSale	−3,366 sh	$56.09	−$189K	6,745
2024-06-20	CRSPCRISPR Therapeutics AGM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+7,000 sh	—	—	10,111
2024-06-20	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−7,000 sh	—	—	0
2024-05-23	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	Chief Operating Officer	AAward	+20K sh	—	—	20,000

Recent filings

Accepted (ET)
Mar 254
Bruno Julianne0001193125-26-124455
SEC(opens sec.gov)
Feb 124
Bruno Julianne0001193125-26-047537
SEC(opens sec.gov)
Mar 244
Bruno Julianne0000950170-25-043974
SEC(opens sec.gov)
Mar 184
Bruno Julianne0000950170-25-041468
SEC(opens sec.gov)
Mar 124
Bruno Julianne0000950170-25-038214
SEC(opens sec.gov)
Feb 194
Bruno Julianne0000950170-25-023387
SEC(opens sec.gov)
Oct 184
Bruno Julianne0000950170-24-115695
SEC(opens sec.gov)
Jun 244
Bruno Julianne0000950170-24-076916
SEC(opens sec.gov)

Companies

Address

C/O DAMORA THERAPEUTICS, INC., 221 CRESCENT ST, BUILDING 23, SUITE 105

WALTHAM, MA, 02453